Separation of two labeled components of [<sup>111</sup>In]-OctreoScan by HPLC

Abstract

[¹¹¹In]-DTPA-D-Phe¹-octreotide (OctreoScan®, Mallinkrodt) is widely used for detection of neuroendocrine tumors and has lately been proposed for radionuclide therapy. We found, using HPLC and a GF-250 column (Zorbax®, Hewlett Packard), that OctreoScan® can be separated in two radiolabeled components of about equal amount. The analytical conditions for a quantitative isolation indicate that the two-peptide components of OctreoScan® have different lipophilicity. The isolated components are stable and do not transform into each other at room temperature during 6 hours (shelf-life of OctreoScan®).

Original language	English
Pages (from-to)	95-99
Number of pages	5
Journal	Journal of Radioanalytical and Nuclear Chemistry
Volume	247
Issue number	1
DOIs	https://doi.org/10.1023/A:1006715114925
Publication status	Published - 2001
Externally published	Yes

ASJC Scopus subject areas

Analytical Chemistry
Nuclear Energy and Engineering
Radiology Nuclear Medicine and imaging
Pollution
Spectroscopy
Public Health, Environmental and Occupational Health
Health, Toxicology and Mutagenesis

Access to Document

10.1023/A:1006715114925

Fingerprint Dive into the research topics of 'Separation of two labeled components of [<sup>111</sup>In]-OctreoScan by HPLC'. Together they form a unique fingerprint.

Cite this

@article{18b8431da2474be3ad9407c8a1160e93,

title = "Separation of two labeled components of [111In]-OctreoScan by HPLC",

abstract = "[111In]-DTPA-D-Phe1-octreotide (OctreoScan{\textregistered}, Mallinkrodt) is widely used for detection of neuroendocrine tumors and has lately been proposed for radionuclide therapy. We found, using HPLC and a GF-250 column (Zorbax{\textregistered}, Hewlett Packard), that OctreoScan{\textregistered} can be separated in two radiolabeled components of about equal amount. The analytical conditions for a quantitative isolation indicate that the two-peptide components of OctreoScan{\textregistered} have different lipophilicity. The isolated components are stable and do not transform into each other at room temperature during 6 hours (shelf-life of OctreoScan{\textregistered}).",

author = "A. Bruskin and V. Tolmachev and Westlin, {J. E.} and H. Lundqvist",

note = "Funding Information: The authors would like to thank The Svedberg Laboratory for technical help and the Swedish Cancer Foundation and the Swedish Royal Academy of Sciences for financial support. Copyright: Copyright 2007 Elsevier B.V., All rights reserved.",

year = "2001",

doi = "10.1023/A:1006715114925",

language = "English",

volume = "247",

pages = "95--99",

journal = "Journal of Radioanalytical and Nuclear Chemistry",

issn = "0236-5731",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Separation of two labeled components of [111In]-OctreoScan by HPLC

AU - Bruskin, A.

AU - Tolmachev, V.

AU - Westlin, J. E.

AU - Lundqvist, H.

N1 - Funding Information: The authors would like to thank The Svedberg Laboratory for technical help and the Swedish Cancer Foundation and the Swedish Royal Academy of Sciences for financial support. Copyright: Copyright 2007 Elsevier B.V., All rights reserved.

PY - 2001

Y1 - 2001

N2 - [111In]-DTPA-D-Phe1-octreotide (OctreoScan®, Mallinkrodt) is widely used for detection of neuroendocrine tumors and has lately been proposed for radionuclide therapy. We found, using HPLC and a GF-250 column (Zorbax®, Hewlett Packard), that OctreoScan® can be separated in two radiolabeled components of about equal amount. The analytical conditions for a quantitative isolation indicate that the two-peptide components of OctreoScan® have different lipophilicity. The isolated components are stable and do not transform into each other at room temperature during 6 hours (shelf-life of OctreoScan®).

AB - [111In]-DTPA-D-Phe1-octreotide (OctreoScan®, Mallinkrodt) is widely used for detection of neuroendocrine tumors and has lately been proposed for radionuclide therapy. We found, using HPLC and a GF-250 column (Zorbax®, Hewlett Packard), that OctreoScan® can be separated in two radiolabeled components of about equal amount. The analytical conditions for a quantitative isolation indicate that the two-peptide components of OctreoScan® have different lipophilicity. The isolated components are stable and do not transform into each other at room temperature during 6 hours (shelf-life of OctreoScan®).

UR - http://www.scopus.com/inward/record.url?scp=0035109710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035109710&partnerID=8YFLogxK

U2 - 10.1023/A:1006715114925

DO - 10.1023/A:1006715114925

M3 - Article

AN - SCOPUS:0035109710

VL - 247

SP - 95

EP - 99

JO - Journal of Radioanalytical and Nuclear Chemistry

JF - Journal of Radioanalytical and Nuclear Chemistry

SN - 0236-5731

IS - 1

ER -